Literature DB >> 28251378

Role of Segmentectomy in Treatment of Early-Stage Non-Small Cell Lung Cancer.

Mark Hennon1,2, Rodney J Landreneau3.   

Abstract

PURPOSE AND
DESIGN: Standard treatment for early-stage non-small cell lung cancer has traditionally involved lobectomy. Historical data that demonstrates suboptimal results for sublobar resection compared to lobectomy have been challenged in recent years with retrospective data for patients with T1a disease. For patients who are not candidates for lobectomy, options for sublobar resection include wedge resection or anatomic segmentectomy. Segmentectomy has long been held to be a better cancer operation than wedge resection, and its role in treating early-stage lung cancer remains controversial in patients who are candidates for lobectomy. A review of available literature involving segmentectomy and possible predictors of failure for segmentectomy was performed in an attempt to clarify the role of segmentectomy for early-stage lung cancer. RESULTS AND
CONCLUSIONS: Current evidence is conflicting regarding the optimal scenario for sublobar resection with segmentectomy. Two large-scale randomized trials are currently addressing the question. In the meantime, certain preoperative and intraoperative considerations should be taken into account when considering segmentectomy for the treatment of early-stage non-small cell lung cancer.

Entities:  

Mesh:

Year:  2017        PMID: 28251378     DOI: 10.1245/s10434-017-5787-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

1.  T1a lung carcinoma: the place of segmentectomy in the treatment array.

Authors:  Sameer A Hirji; Scott J Swanson
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 2.  Is segmentectomy the future?

Authors:  Rodney J Landreneau; Matthew J Schuchert
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

Review 3.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 2: systematic review of evidence regarding resection extent in generally healthy patients.

Authors:  Frank C Detterbeck; Vincent J Mase; Andrew X Li; Ulas Kumbasar; Brett C Bade; Henry S Park; Roy H Decker; David C Madoff; Gavitt A Woodard; Whitney S Brandt; Justin D Blasberg
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

4.  Thoracoscopic segmentectomy with simple routine bronchoscopic inflation for intersegmental plane identification: short and mid-term outcomes compared with lobectomy.

Authors:  Olli Helminen; Johanna Valo; Heidi Andersen; Anna Lautamäki; Jari Räsänen; Eero Sihvo
Journal:  J Thorac Dis       Date:  2020-06       Impact factor: 2.895

5.  Intraoperative diagnosis of lymph node metastasis during segmentectomy for non-small cell lung cancer by rapid immunohistochemistry using noncontact alternating current electric field mixing.

Authors:  Kazuhiro Imai; Hiroshi Nanjo; Shinogu Takashima; Yuko Hiroshima; Maiko Atari; Tsubasa Matsuo; Shoji Kuriyama; Yoshiaki Ishii; Yuki Wakamatsu; Yusuke Sato; Satoru Motoyama; Hajime Saito; Kyoko Nomura; Yoshihiro Minamiya
Journal:  Thorac Cancer       Date:  2020-10-19       Impact factor: 3.500

6.  Evolution of the surgical treatment of lung cancer at a tertiary referral center in Brazil, 2011-2018.

Authors:  Mariana Schettini Soares; Laura Maria Coltro; Pedro Henrique Cunha Leite; Priscila Berenice Costa; Letícia Leone Lauricella; Paulo Manuel Pêgo-Fernandes; Ricardo Mingarini Terra
Journal:  J Bras Pneumol       Date:  2020-12-16       Impact factor: 2.624

Review 7.  Current Surgical Indications for Non-Small-Cell Lung Cancer.

Authors:  Nathaniel Deboever; Kyle G Mitchell; Hope A Feldman; Tina Cascone; Boris Sepesi
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

8.  Establishment of a Nomogram-Based Prognostic Model (LASSO-COX Regression) for Predicting Progression-Free Survival of Primary Non-Small Cell Lung Cancer Patients Treated with Adjuvant Chinese Herbal Medicines Therapy: A Retrospective Study of Case Series.

Authors:  Bin Luo; Ming Yang; Zixin Han; Zujun Que; Tianle Luo; Jianhui Tian
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

9.  A systematic review and meta-analysis of the influence of STAS on the long-term prognosis of stage I lung adenocarcinoma.

Authors:  Yanhui Yang; Xiaoyang Xie; Yi Wang; Xiaoliang Li; Lei Luo; Yi Yao; Ji Li
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.